Sign up
Pharma Capital

Bond repayment amendment to give Collagen Solutions 'greater flexibility to exploit opportunities'

Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy and CFO Hilary Spence speak to Proactive London about news just out on the realignment of bond payments with financing partner Norgine Ventures, which will allow the biomaterials company to 'leverage medium to long term growth opportunities'.

Current efforts to launch ChondroMimetic® are progressing according to plan, and Spence confirms that the company is, "absolutely remaining on track for financial performance and market expectations for this financial year."

 

View full COS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.